PRESS RELEASE published on 01/29/2024 at 17:40, 2 years 1 month ago Valbiotis presents its 2024 financial communication calendar Valbiotis presents its 2024 financial communication calendar. The company specializing in dietary supplements announces publication dates for the 2023 annual report and 2024 half-year report, as well as the Annual General Meeting Financial Communication Calendar Valbiotis Dietary Supplements Metabolic Diseases Cardiovascular Diseases
PRESS RELEASE published on 11/07/2023 at 17:40, 2 years 3 months ago Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
PRESS RELEASE published on 10/02/2023 at 17:40, 2 years 5 months ago VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes
PRESS RELEASE published on 09/28/2023 at 17:40, 2 years 5 months ago Valbiotis publishes its financial report for the first half of 2023 and confirms its strategic roadmap
PRESS RELEASE published on 09/11/2023 at 17:40, 2 years 5 months ago VALBIOTIS SA: Valbiotis presents the full results of the Phase II/III REVERSE-IT study: impressive efficacy of TOTUM•63 against prediabetes and the early stages of type 2 diabetes
PRESS RELEASE published on 07/12/2023 at 17:40, 2 years 7 months ago Valbiotis announces its roadmap and strategic priorities on the eve of key milestones for its portfolio of innovative active substances
PRESS RELEASE published on 07/03/2023 at 17:40, 2 years 7 months ago Valbiotis announces the appointment of Charlotte JEZEQUEL as Director of Human Relations and Executive Committee member
Published on 03/02/2026 at 22:02, 1 hour 17 minutes ago Unusual Machines to Announce Fourth Quarter and Full-Year 2025 Financial Results and Provide Corporate Update
Published on 03/02/2026 at 22:00, 1 hour 19 minutes ago Justera Announces Definitive Agreement to Sell Port North Extracts Inc. and Resignations
Published on 03/02/2026 at 18:35, 4 hours 44 minutes ago Electrovaya Announces Results of Annual Meeting of Shareholders
Published on 03/02/2026 at 17:40, 5 hours 39 minutes ago Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
Published on 03/02/2026 at 22:45, 34 minutes ago Huawei New-Gen OceanStor Dorado Converged All-Flash Storage Passes Enterprise Strategy Group Technical Validation
Published on 03/02/2026 at 21:30, 1 hour 49 minutes ago Huawei Launches the Xinghe Intelligent Traffic-Encryption Integration Solution to Build a Quantum-Secure Foundation for WANs
Published on 03/02/2026 at 21:13, 2 hours 5 minutes ago Voluntary tender offer for all ordinary shares of NEXT RE SIIQ S.p.A.
Published on 03/02/2026 at 21:00, 2 hours 19 minutes ago Huawei Li Peng: Accelerating Towards the Agentic Internet Era with 5G-A and AI
Published on 03/02/2026 at 19:50, 3 hours 28 minutes ago EQS-Adhoc: Beiersdorf Aktiengesellschaft: Guidance 2026 –– New Share Buyback Program
Published on 03/02/2026 at 17:35, 5 hours 44 minutes ago Disclosure of transactions in own shares from February 23 to February 27, 2026
Published on 03/02/2026 at 08:45, 14 hours 34 minutes ago Imerys: 2025 consolidated financial statements
Published on 02/27/2026 at 23:00, 3 days ago Biophytis increases to €2 million the ceiling of its bond facility with Hexagon Capital Fund
Published on 02/27/2026 at 18:02, 3 days 5 hours ago AXA: Execution of a share repurchase agreement in relation to AXAs share buy-back program of up to Euro 1.25 billion
